Nicotinamide Mononucleotide Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a β-nicotinamide mononucleotide active substance supplied as a white to off-white crystalline powder. The CAS registry number is 1094-61-7, the molecular formula is C11H15N2O8P, and the anhydrous molecular mass is 334.22 g/mol. The product is not a finished dosage form; it is an active pharmaceutical ingredient whose grade model is selected according to the intended dosage-form process and route of administration. Product models are segregated by intended route and processing path rather than by chemical identity: oral direct-compression grade, capsule-grade powder, granule-grade powder, and injectable-grade low-endotoxin powder. Each grade differs principally in residual water, bioburden, endotoxin, and particle-size acceptance criteria; the underlying molecular structure is unchanged.

Release specification envelope and pharmacopoeial method alignment

Representative release limits for commercial NMN API are summarised in the following table. These values are drawn from typical certificate-of-analysis parameters; because no harmonised pharmacopoeial monograph is published for nicotinamide mononucleotide, the method designator is aligned with the applicable general chapter.

For oral solid dosage forms, the assay is normalised on the anhydrous, solvent-free basis; loss on drying is not used as a substitute for Karl Fischer water determination because surface moisture and hydrate water can differ. HPLC methods commonly use a reversed-phase column with dimensions of 250 mm × 4.6 mm packed with 5 µm C18 silica, detection at 254 nm, and an isocratic mobile phase comprising phosphate buffer and methanol. The β-anomer peak is integrated against a working standard of known purity. Total impurities are controlled with a reporting threshold of 0.05 area% and an identification threshold of 0.10 area%, following ICH Q3A principles. For injectable use, endotoxin testing is added and a pre-filtration bioburden limit of ≤10 CFU/100 mL is applied to the bulk solution before sterilising filtration.

Processing of oral solid dosage forms with NMN is dominated by the hygroscopic phosphate-ester structure and the need to control moisture below the point at which the powder loses compressibility. Bulk and tapped densities are measured according to USP <616>; a Hausner ratio above 1.35 indicates the need for roller compaction or wet granulation before tablet compression. Direct-compression grade NMN is typically pre-blended with colloidal silicon dioxide at 0.5–1.0 wt% and sodium stearyl fumarate at 0.5–1.5 wt%; magnesium stearate may be used but over-lubrication above 2.0 wt% can reduce tablet tensile strength. On a rotary tablet press fitted with 10.0 mm round B-tooling, feed-frame speed is maintained between 20–40 rpm and compression force is adjusted to achieve a target hardness of 60–100 N for tablets with a mass of 300 mg. The finished tablet must meet disintegration not more than 15 min in purified water at 37.0 °C per USP <701> and dissolution not less than 80% in 30 min using USP <711> Apparatus 2 at 50 rpm in 900 mL water. For capsules, a dosator-type capsule filler with size 0 capsules is used; the tamping-pin station is adjusted to produce a target fill weight tolerance of ±5%. The low bulk density of untreated NMN powder can require densification by slugging or dry granulation before encapsulation; if the as-received poured density is below 0.30 g/mL, the flowability may not support weight uniformity at production speeds above 60,000 capsules/h.

For granule-grade NMN intended for sachets or suspension, high-shear or fluid-bed granulation is employed. In a high-shear mixer, purified water is added at 10–20 wt% of dry powder mass; impeller tip speed is held between 5–10 m/s and chopper speed between 1500–3000 rpm for 3–6 min to reach a median granule size of 150–250 µm by laser diffraction per USP <429>. The wet mass is transferred immediately to a fluid-bed dryer; inlet air temperature is limited to 40–50 °C to avoid solution-phase hydrolysis. The final granule moisture is confirmed below 1.0% by Karl Fischer titration before terminal blending. If the granules are to be filled into stick packs, the final blend is passed through a 1.0 mm conical screen and the moisture is checked again at the fill-line hopper.

Why does the injectable grade require a different pyrogen and particulate-control strategy than oral powder?

Injectable administration requires the API to be free of bacterial endotoxins and to meet particle-count limits that are irrelevant for tablets or capsules. For NMN injectable grade, the bacterial endotoxin limit is ≤0.25 EU/mg by kinetic chromogenic LAL per USP <85>, and the bulk solution is filtered through a 0.22 µm polyethersulfone sterilising-grade filter before aseptic filling. The filling line is operated in an ISO 5 unidirectional airflow environment defined by ISO 14644-1, with glove-box or restricted-access-barrier systems used to reduce human intervention; this is consistent with EU GMP Annex 1. Terminal sterilisation is avoided for NMN unless the formulation is shown to survive moist heat; published data for this specific configuration is limited. After filling, each container is inspected for visible particles per USP <790>. For subvisible particles, the light-obscuration method of USP <787> is used; limits for small-volume injections are ≤6000 particles ≥10 µm and ≤600 particles ≥25 µm per container. The injectable grade also has a residual moisture limit of ≤0.5% because free moisture can promote hydrolysis and may alter the lyophilisation cake or solution clarity. pH adjustment is performed after complete dissolution with 0.1 N HCl or NaOH to a target of 6.0–7.0; the product is not a buffered solution unless a specific buffer salt is added, and the use of phosphate buffer must be evaluated for compatibility with calcium-containing infusion fluids.

The principal product difference between NMN and other nicotinamide-based NAD-precursor ingredients is the presence of the phosphate group on the ribose. Nicotinamide riboside chloride has a molecular mass of 290.70 g/mol and is a cationic molecule at acidic formulation pH, whereas NMN is dianionic at neutral pH; this changes its interaction with croscarmellose sodium, sodium starch glycolate, and methacrylic acid copolymers. Nicotinamide itself has a molecular mass of 122.12 g/mol, is uncharged, and is far less hygroscopic; it can be wet-granulated without the same degree of moisture sensitivity. From a purification standpoint, NMN contains a β-glycosidic bond and a phosphate ester; the main process-related impurities include the α-anomer, nicotinamide, ribose phosphate, and residual solvents. In oral tablet formulations, the α-anomer is controlled at not more than 1.0–2.0% because it may not be biologically equivalent; HPLC method capability rather than pharmacopoeial specification currently governs this limit. Injectable NMN differs from oral NMN in that the injectable grade cannot be simply an oral powder that has been sterilised; the incoming API must already have low bioburden and low endotoxin because terminal filtration does not remove soluble endotoxin.

When NMN is dissolved for parenteral or granulation fluids

The behavior of NMN in water determines the critical handling limits in both granulation and injectable preparation. In water, the phosphate group dissociates and can reduce the pH of an unbuffered solution; a 1.0% w/v aqueous solution may fall in the acidic range, and the exact value depends on residual counterion content. The solution is therefore pH-adjusted rather than simply hydrated. For wet granulation, a 10–20 wt% water level is used to avoid a continuous free-water phase; the addition rate is set so that the wet mass reaches a target loss-on-drying of 8–12% before entering the dryer. The granules are then screened through a 1.0 mm screen and dried to ≤1.0% moisture. In injectable compounding, dissolved oxygen is reduced by nitrogen sparging to below 0.5 mg/L, and the solution is held at 2–8 °C for not more than 24 h before sterile filtration to limit hydrolysis; this hold-time is based on general aseptic processing practice because published forced-degradation data for NMN under these exact conditions is limited. The use of phosphate-buffered vehicle is evaluated for precipitation risk; calcium-containing diluents should be avoided because the phosphate group can form insoluble calcium phosphate complexes.

Packaging for oral tablet/capsule/granule grade uses double low-density polyethylene liners sealed in aluminium foil laminate with a desiccant; storage is at 15–25 °C and ≤35% RH. The injectable grade is supplied in Type I glass vials with bromobutyl stoppers, stored at 2–8 °C and protected from light. The material is re-tested every 24 months for oral grade and every 12 months for injectable grade under ICH Q1A(R2)-compliant stability protocols. For shipment, temperature excursion below 0 °C is permitted for injectable grade only if moisture ingress is prevented, while oral grade does not require cold-chain transport. Published data for this specific configuration is limited.

The injectable and oral grades are released against the following compliance anchors.

Release and formulation activities are referenced to the following standards and guidance documents. The absence of a specific NMN monograph in USP, Ph. Eur., or JP means that the listed general chapters are applied as scientifically appropriate rather than as compendial requirements for the molecule.